New hope for rare uterine cancer: targeted drug shows promise in trial

NCT ID NCT02491099

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 41 times

Summary

This study tests a drug called afatinib in people with a rare and aggressive uterine cancer (HER2-positive uterine serous carcinoma) that has come back or not gone away. The goal is to see if the drug can stop the cancer from growing for at least 6 months. About 50 participants will take afatinib pills daily, and researchers will monitor tumor response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2/NEU+ UTERINE SEROUS CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Massachusetts General Hospital
COMPLETED

Boston, Massachusetts, 02114, United States
University of Arizona Cancer Center
COMPLETED

Tucson, Arizona, 85724, United States
Yale New Haven Hospital
RECRUITING

New Haven, Connecticut, 06510, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HER2/NEU+ UTERINE SEROUS CARCINOMA